IDORSIA AG SF-,05 WKN A2DTEB | ISIN CH0363463438 | Aktie Watchlist Musterdepot Alert Factsheet 02.06.24 19:03:37 RT Bid: 2,652 EUR | Ask: 2,722 EUR 2,652 EUR +0,00 % (+0,000) Lang & Schwarz SIX Swiss Exchange Nasdaq Other OTC Baader Bank (Baadex) Lang & Schwarz Berlin EUREX gettex Hamburg München Verkaufen Kaufen Übersicht Chart-Pro Analysen Nachrichten Kurse & Handelsplätze Letzte Umsätze 28.02.24 GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collaboration 28.02.24 Idorsia and Viatris enter into a significant global research and development collaboration 10.01.24 GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for sustainable value creation 03.11.23 GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 03.11.23 New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 24.10.23 GNW-Adhoc: Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt - Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert 23.10.23 GNW-Adhoc: Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023 17.10.23 GNW-Adhoc: Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call 06.09.23 GNW-Adhoc: Idorsia reacquires the world-wide rights to aprocitentan 25.07.23 GNW-Adhoc: Idorsia gibt Finanzergebnisse für das erste Halbjahr 2023 bekannt - Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert 21.07.23 GNW-Adhoc: Idorsia kündigt eine Kostensenkungsinitiative an, die bis Ende 2023 umgesetzt werden soll 20.07.23 GNW-Adhoc: Idorsia sells its Asia Pacific (ex-China) operations - including select license rights to products - to Sosei Heptares for a total consideration of CHF 400 million 18.07.23 GNW-Adhoc: Invitation to Idorsia's HY 2023 Financial Results webcast and conference call 10.07.23 GNW-Adhoc: Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS 26.06.23 GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023